TxCell SA - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 25 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

TxCell SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'TxCell SA - Product Pipeline Review - 2014', provides an overview of the TxCell SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of TxCell SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of TxCell SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of TxCell SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the TxCell SA's pipeline products

Reasons to buy

- Evaluate TxCell SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of TxCell SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the TxCell SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of TxCell SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of TxCell SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of TxCell SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
TxCell SA Snapshot 4
TxCell SA Overview 4
Key Information 4
Key Facts 4
TxCell SA - Research and Development Overview 5
Key Therapeutic Areas 5
TxCell SA - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
TxCell SA - Pipeline Products Glance 9
TxCell SA - Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
TxCell SA - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
TxCell SA - Drug Profiles 12
Ova-Treg 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Col-Treg 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
TX-RAD 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
HSP60-Treg 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Myelin-Treg 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
TxCell SA - Pipeline Analysis 18
TxCell SA - Pipeline Products by Route of Administration 18
TxCell SA - Pipeline Products by Molecule Type 19
TxCell SA - Recent Pipeline Updates 20
TxCell SA - Dormant Projects 22
TxCell SA - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25

List of Tables
TxCell SA, Key Information 4
TxCell SA, Key Facts 4
TxCell SA - Pipeline by Indication, 2014 6
TxCell SA - Pipeline by Stage of Development, 2014 7
TxCell SA - Monotherapy Products in Pipeline, 2014 8
TxCell SA - Phase I, 2014 9
TxCell SA - Preclinical, 2014 10
TxCell SA - Discovery, 2014 11
TxCell SA - Pipeline by Route of Administration, 2014 18
TxCell SA - Pipeline by Molecule Type, 2014 19
TxCell SA - Recent Pipeline Updates, 2014 20
TxCell SA - Dormant Developmental Projects,2014 22